[NVIC] HPV Vaccine Increases Cancer Risk

Vienna, Virginia http://www.nvic.org

* * * * * * * * * * * * * * * * * * * * * * *
* * * * * * * * * * * * * * * * * * * * * * *

"Protecting the health and informed consent rights of children since 1982."

BL Fisher Note:
  Gardasil, the heavily promoted cervical cancer and genital wart vaccine
that Merck, the CDC and AAP want to mandate for all 11 and 12 year old
girls, will not only increase the risk of cervical cancer for some of
adolescent girls but can also make them susceptible to infection from the
multiple other strains of HPV. In addition, five women who got the vaccine
around time of conception gave birth to babies with birth defects.

   With American babies now getting 48 doses of 14 vaccines by age six,
profit-hungry drug companies and power-hungry federal health officials are
targeting adolescents for new vaccine consumption. During a time when
adolescents are undergoing hormonal changes and accelerated growth, they are
being subjected to increased atypical manipulation of the immune system with
viral and bacterial vaccines including DTaP, meningococcal, flu, hepatitis B
and now a genital wart and cervical cancer vaccine.

  In this national experiment on our teenagers, will anybody be studying
onset of chronic disease and disability in adolescents post vaccination? Or
will predictable increases in brain and immune system dysfunction such as
onset of new allergies, asthma, seizure disorders, multiple sclerosis,
rheumatoid arthritis, diabetes, irritable bowel syndrome, thyroid disease,
chronic fatigue, depression, and yes, cancer, be written off as unassociated
with vaccination?

   Injecting adolescent girls with any vaccine that could increase their
chance of getting cancer without their voluntary, informed consent and the
consent of their parents is immoral. All attempts to mandate Gardasil for
school entry should be opposed as a violation of human rights, including the
right to life.


The Washington Post

FDA: Cervical cancer vaccine safe
Gardasil prevents four types of HPV

Wednesday, May 17, 2006

WASHINGTON (AP) -- A vaccine that blocks infection by the four virus types
that cause most cervical cancers and genital warts appears safe and
effective, but may actually increase the chance of disease in some patients,
according to Food and Drug Administration documents released Wednesday.

Merck & Co. seeks FDA approval for its Gardasil vaccine against four types
of human papilloma virus, or HPV. Two of those four types are believed
responsible for about 70 percent of cervical cancer cases. The cancer kills
roughly 3,500 U.S. women a year; the other two types cause 90 percent of
genital wart cases.

An FDA panel of outside experts is to meet Thursday and discuss whether to
recommend that the agency approve the vaccine. The FDA isn't required to
follow the advice of its expert panels but usually does.

According to briefing documents released ahead of the meeting, the panel
should discuss various items of concern only if its members first agree that
studies show the vaccine is safe and effective. That suggests the FDA favors
its approval.

Merck said the vaccine has the potential to reduce the annual number of new
cervical cancers worldwide to roughly 150,000, from the current 500,000, and
cut global deaths from the cancer by more than two-thirds, to an estimated

An FDA review of the results of studies on the vaccine found two important
concerns, according to the documents released ahead of Thursday's meeting of
the Vaccines and Related Biological Products advisory committee.

The first is that the vaccine may lead to an increased number of cases of a
cancer precursor among patients already infected by any of the four virus
types at the time they receive the vaccine, and whose immune systems have
not cleared the virus from their bodies.

The second concern is that any advantage the vaccine provides in protecting
against the four virus types could be offset by infection by any of the
multiple other types of HPV that the vaccine does not cover, according to
the FDA documents.

FDA staff also asked that the committee examine five cases where children
with birth defects were born to women who had received the vaccine around
the time of conception.

Merck developed the vaccine and tested it in both women and men, but
Thursday's discussion is expected to focus on its use in preventing
HPV-related disease in women.

An FDA decision is expected by June 8. Should it approve it, the national
Advisory Committee on Immunization Practices will decide later that month
whether to endorse routine vaccination with the vaccine.

The committee's HPV vaccine workgroup is recommending the vaccine be given
to girls 11 and 12, and the committee will consider recommendations for
females 13 to 26.

News@nvic.org is a free service of the National Vaccine Information
Center and is supported through membership donations.  Learn more about
vaccines, diseases and how to protect your informed consent rights

Become a member and support NVIC's work

To sign up for a free e-mail subscription http://www.nvic.org/emaillist.htm

To unsubscribe from this list, please go to
http://nvic.org/emaillistunsub.htm or send an email to
news-request@nvic.org and type UNSUBSCRIBE in the body of the email.

NVIC is funded through individual membership donations and does not receive
government funding. Barbara Loe Fisher, President and Co-founder.
NOTE: This is not an interactive e-mail list. Please do not respond to